PART I Overview We are a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from severe ischemic disease with two main clinical programs focused on preeclampsia (PE) / fetal growth restriction (FGR) and acute ischemic stroke (AIS). Our lead candidate DM199 (rinvecalinase alfa), is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (rhKLK1) protein to be clinically studied in patients and has been granted Fast...
Q2 FY2026 — expected 2026-08-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001437749-26-010342 | EDGAR | 77K words |
| 2025-03-17 | 2024-12-31 | 0001437749-25-008018 | EDGAR | — |
| 2024-03-19 | 2023-12-31 | 0001437749-24-008522 | EDGAR | — |
| 2023-03-28 | 2022-12-31 | 0001437749-23-008189 | EDGAR | — |
| 2022-03-14 | 2021-12-31 | 0001437749-22-006163 | EDGAR | — |
| 2021-03-10 | 2020-12-31 | 0001437749-21-005541 | EDGAR | — |
| 2020-03-23 | 2019-12-31 | 0001437749-20-005906 | EDGAR | — |
| 2019-03-19 | 2018-12-31 | 0001437749-19-005272 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001437749-25-034469 | EDGAR | 19K words |
| 2025-08-12 | 2025-06-30 | 0001437749-25-026207 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001437749-25-016488 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001437749-24-034925 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0001437749-24-025198 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0001437749-24-015381 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001437749-23-031671 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001437749-23-023708 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001437749-23-014616 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001437749-22-026609 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001437749-22-019848 | EDGAR | — |
| 2022-05-04 | 2022-03-31 | 0001437749-22-010876 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001437749-26-010409 | EDGAR | 4K words |
| 2026-01-05 | 0001437749-26-000175 | EDGAR | — |
| 2025-12-18 | 0001437749-25-038211 | EDGAR | — |
| 2025-11-12 | 0001437749-25-034467 | EDGAR | — |
| 2025-08-12 | 0001437749-25-026286 | EDGAR | — |
| 2025-08-12 | 0001437749-25-026205 | EDGAR | — |
| 2025-08-06 | 0001437749-25-024956 | EDGAR | — |
| 2025-07-21 | 0001437749-25-023048 | EDGAR | — |
| 2025-07-17 | 0001437749-25-022877 | EDGAR | — |
| 2025-05-15 | 0001437749-25-017239 | EDGAR | — |
132 total filings indexed. 102 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001401040 |
| Ticker | DMAC |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | Z4 |
| Website | https://www.diamedica.com |
| Listed | 2007-11-29 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report